Characteristic morphological changes in anti‐<scp>VEGF</scp> therapy‐induced glomerular microangiopathy

Abstract

aVEGF therapy-induced glomerular microangiopathy has a characteristic morphology and clinical presentation that helps to differentiate it from other causes of TMA. Awareness of these light microscopic findings allows identification of aVEGF therapy as a trigger of renal disease in critically ill cancer patients, and might therefore help in deciding on further therapy.